Erica Farrand, MD
Assistant Professor
Medicine
School of Medicine

Dr. Farrand is an Assistant Professor in the Division of Pulmonary, Critical Care, Sleep, Allergy and Sleep Medicine. She is attending physician in the Interstitial Lung Disease Program and on the Pulmonary Consult Service.

Show full bio (60 words) Hide full bio

Dr. Farrand's scholarship focuses on defining, assessing and improving the health care quality, safety and outcomes for individuals with interstitial lung disease. She collaborates closely with colleagues in ILD, health services research, implementation science and clinical informatics to support a multidisciplinary research program that aims to integrate digital health interventions to improve the delivery of chronic lung disease care.

Awards

Show all (1) Hide

• Young Physician Scientist Award, The American Society for Clinical Investigation, 2025

Education & Training

Show all (5) Hide

• Diversity, Equity, and Inclusion Champion Training University of California, San Francisco 2020
• Pulmonary and Critical Care University of California, San Francisco 2019
• Advanced Training in Clinical Research Certificate University of California, San Francisco 2019
• Internal Medicine NYP-Columbia University 2013
• School of Medicine Columbia University 2010

Interests

Show all (7) Hide

• digital health
• real world data
• clinical informatics
• chronic lung disease
• artificial intelligence
• remote monitoring
• interstitial lung disease

Websites

Show all (1) Hide

• Posts on X ericafarrandMD (X.com)

Grants and Projects

Show all (6) Hide

• Remote Evaluation and Surveillance of Patients with Interstitial Lung Disease (RESPOND-ILD): Transforming ILD Care Delivery with Remote Monitoring, NIH, 2024-2029
• Improving Delivery of Evidence-Based Care in Idiopathic Pulmonary Fibrosis, NIH/NHLBI, 2020-2023
• The Future of Telehealth in Interstitial Lung Disease, CHEST Foundation, 2020-2022
• Harnessing the Power of the Electronic Medical Record in Interstitial Lung Disease, Nina Ireland Program in Lung Health, 2020-2022
• Closing the Evidence Gap in ILD: The Use of Real World Observational Cohorts to Understand the Natural History of Fibrotic Lung Disease, Pulmonary Fibrosis Foundation, 2019-2021
• Clinical practice patterns and healthcare resource utilization in acute exacerbation of idiopathic pulmonary fibrosis: using real world data to bridge the evidence gap, NIH, 2018-2019

Publications (21)

Top publication keywords:
Patient Acceptance of Health CareLung NeoplasmsLung Diseases, InterstitialHospitalizationTelemedicineAdrenal Cortex HormonesElectronic Health RecordsTreatment FailureHospitalistsIdiopathic Pulmonary FibrosisTerminal CareClinical Trials as TopicVaccinesPalliative CarePulmonary Disease, Chronic Obstructive

• Differences in Health Care and Palliative Care Use at the End of Life: A Comparison Study Among Lung Cancer, COPD, and Idiopathic Pulmonary Fibrosis.
  Chest 2024 Suen AO, Bischoff K, Iyer AS, Radhakrishnan K, Fenton C, Singer JP, Sudore RL, Kotwal A, Farrand E
• Phage Immunoprecipitation-Sequencing Reveals CDHR5 Autoantibodies in Select Patients With Interstitial Lung Disease.
  ACR open rheumatology 2024 Upadhyay V, Yoon YM, Vazquez SE, Velez TE, Jones KD, Lee CT, Law CS, Wolters PJ, Lee S, Yang MM, Farrand E, Noth I, Strek ME, Anderson MS, DeRisi JL, Sperling AI, Shum AK
• Steroid therapy in acute exacerbation of fibrotic interstitial lung disease.
  Respirology (Carlton, Vic.) 2024 Koshy K, Barnes H, Farrand E, Glaspole I
• Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.
  Chest 2023 Mullin ML, Fernandez G, Marinescu DC, Zheng B, Wong AW, Assayag D, Fisher JH, Johannson KA, Khalil N, Kolb M, Manganas H, Marcoux V, Morisset J, Min B, Farrand E, Ryerson CJ
• National Prevalence of Social Isolation and Loneliness in Adults with Chronic Obstructive Pulmonary Disease.
  Annals of the American Thoracic Society 2023 Suen AO, Iyer AS, Cenzer I, Farrand E, White DB, Singer J, Sudore R, Kotwal A

Show all (16 more) Hide

• Digital outcome measures in pulmonary clinical trials.
  Current opinion in pulmonary medicine 2023 Farrand E, Swigris JJ
• Machine-Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease.
  American journal of respiratory and critical care medicine 2023 Farrand E, Gologorskaya O, Mills H, Radhakrishnan L, Collard HR, Butte AJ
• Extracting patient-level data from the electronic health record: Expanding opportunities for health system research.
  PloS one 2023 Farrand E, Collard HR, Guarnieri M, Minowada G, Block L, Lee M, Iribarren C
• Addressing health disparities through implementation science-a need to integrate an equity lens from the outset.
  Implementation science : IS 2022 Kerkhoff AD, Farrand E, Marquez C, Cattamanchi A, Handley MA
• Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease.
  Chest 2021 Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR,…
• Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination.
  Thorax 2021 DeDent AM, Farrand E
• Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems.
  Clinics in chest medicine 2021 Farrand E, Limper AH
• Strategies for forming effective women's groups.
  The clinical teacher 2020 Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ
• Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients.
  Chest 2020 Farrand E, Iribarren C, Vittinghoff E, Levine-Hall T, Ley B, Minowada G, Collard HR
• Is corticosteroid use truly not associated with improved outcomes in AE-IPF? - Reply.
  Respirology (Carlton, Vic.) 2020 Farrand E, Collard HR
• Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF.
  Respirology (Carlton, Vic.) 2019 Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR
• Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data.
  American journal of respiratory and critical care medicine 2019 Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez FJ, Collard HR
• The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer.
  Journal of hospital medicine 2017 Farrand E, Shah R, Collard H
• Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.
  Digestive diseases and sciences 2012 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL
• Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus.
  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012 Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS
• Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
  Transplantation 2011 Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV, Brown RS